Small-Molecule Targeted Cancer Therapies: World Market 2011-2021

NEW YORK, Dec. 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Small-Molecule Targeted Cancer Therapies: World Market 2011-2021

http://www.reportlinker.com/p0733756/Small-Molecule-Targeted-Cancer-Therapies-World-Market-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

What does the future hold for small-molecule cancer treatments? Visiongain's report shows you potential revenues to 2021, discussing trends and opportunities in that market.

Find revenue predictions at overall world market, product and national levels to 2021. Through our research and analysis we aim to save you time and help in your decisions. 

Where are the 10 leading drugs heading? Find out how products such as Glivec/Gleevec, Revlimid, Alimta, Taxotere, Velcade and Tarceva can perform to 2021. See potential revenues and other trends.

Discover prospects for Novartis, Celgene, Eli Lilly, Sanofi, Roche, Pfizer and other companies. Many commercial opportunities in targeted cancer treatment remain.

Which national markets will achieve the fastest revenue growth? Our report shows you and explains. The targeted small-molecule cancer drug market will expand this decade.

There is a strong R&D pipeline. You can review candidates for treating lung, breast, colorectal, stomach and prostate cancers, as well as multiple myeloma. Also, review immunomodulators, apoptosis inducers, epigenetic agents and other technologies. 

How will changes in the pharma industry affect small-molecule cancer treatments? Our study discusses personalised medicine and other developments, as well as competition. Find out how events this decade will affect the industry and market for anti-cancer drugs. 

Our report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. You can receive answers now in our work.

Revenue forecasts, market shares, developmental trends, discussions and interviews

In our report you find revenue forecasts, growth rates, market shares, qualitative analyses (incl. SWOT and STEP), an R&D review and opinion from our survey. You receive 109 tables and charts and two research interviews.

Advantages of Small-Molecule Targeted Cancer Therapies: World Market 2011-2021 for your work

Our report gives you the following advantages in particular:• Find predicted revenues to 2021 for the targeted small-molecule cancer drug market at world level, seeing revenue growth• Discover revenue forecasts to 2021 for leading products, assessing market potentials• Receive revenue forecasts to 2021 for the US, Japan, Germany, France, theUK, Spain, Italy, China and India• Review R&D for treating a range of cancers, seeing pipeline trends in oncology• Investigate competition and opportunities influencing the industry and market• Find out what will stimulate and restrain the industry and market from 2011• View opinion from our survey, receiving detailed interview transcripts.

There, you find a distinctive mix of quantitative and qualitative analyses with independent predictions. We tackle many questions on cancer treatment, helping you to stay ahead.

Gain industry and market analysis now for small-molecule anti-cancer drugs 

Visiongain is a trading partner with the US Federal GovernmentCCR Ref number: KD4R6  

Table of Contents

1.1 Overview of Findings 

1.2 Scope and Format of the Report

1.3 Research and Analysis Methods

2. Introduction: Cancer, its Physiology, Burden and Treatment2.1 Targeted Cancer Therapies2.2 The Physiology of Cancer2.2.1 Uncontrolled Growth2.2.2 Dedifferentiation2.2.3 Invasiveness and Metastasis2.2.4 Causes of Cancer2.3 Incidence and Mortality for Cancer2.3.1 Incidence2.3.2 Mortality2.3.3 Survival2.3.3.1 The Developed World2.3.3.2 The Developing World2.4 Treating Tumours2.4.1 Chemotherapy2.4.2 Traditional Antineoplastics2.4.3 Novel Antineoplastics2.4.3.1 Kinase Receptor Antagonists2.4.3.2 Other Novel Antineoplastics2.4.4 Hormone Therapies2.4.5 Active Immunotherapy2.4.6 Passive Immunotherapy: Monoclonal Antibodies2.5 Small-Molecule Targeted Cancer Therapies2.5.1 Signal Transduction Inhibitors2.5.2 Gene Expression and Other Cellular Function Regulators2.5.3 Small-Molecule Apoptotic Inducing Drugs2.5.4 Angiogenesis Blockers2.6 Targeted Cancer Therapies: Small-Molecule Drugs

3. The Small-Molecule Cancer Therapies Market, 2011-2021

3.1 The World Small-Molecule Cancer Therapies Market in 2010 

3.2 Growing Market for Small-Molecule Cancer Therapies

3.2.1 Sales Forecast for Small-Molecule Cancer Therapies, 2011-2015

3.2.2 Sales Forecast for Small-Molecule Cancer Therapies, 2016-2021

3.3 Leading Products in Small-Molecule Cancer Therapies Market

4. Small-Molecule Cancer Therapies: Leading National Markets, 2011-20214.1 The US Small-Molecule Cancer Therapies Market, 2011-20214.2 The Japanese Small-Molecule Cancer Therapies Market, 2011-20214.3 The Leading European Small-Molecule Cancer Therapies Markets, 2011-20214.4 Emerging-Economy Small-Molecule Cancer Therapies Markets4.5 The Chinese Small-Molecule Cancer Therapies Market, 2011-20214.6 The Indian Small-Molecule Cancer Therapies Market, 2011-20214.7 Summary of Market Forecasts

5. Leading Small-Molecule Anti-Cancer Products, 2011-2021

5.1 Glivec/Gleevec (Novartis)

5.1.1 Glivec/Gleevec Sales 2010

5.1.2 Glivec/Gleevec Sales Forecast, 2011-2015

5.1.3 Glivec/Gleevec Sales Forecast, 2016-2021

5.1.4 Tasigna Set to Replace Glivec/Gleevec

5.2 Revlimid (Celgene)

5.2.1 Revlimid Sales 2010

5.2.2 Secondary Malignancies

5.2.3 Revlimid Sales Forecast, 2011-2015

5.2.4 Revlimid Sales Forecast, 2016-2021

5.3 Alimta (Eli Lilly)

5.3.1 Alimta Sales 2010

5.3.2 Patent Disputes

5.3.3 Alimta Sales Forecast, 2011-2015

5.3.4 Alimta Sales Forecast, 2016-2021

5.4 Taxotere (Sanofi)

5.4.1 Taxotere Sales 2010

5.4.2 Patent Expiry

5.4.3 Taxotere Sales Forecast, 2011-2015

5.4.4 Taxotere Sales Forecast, 2016-2021

5.5 Velcade (Takeda/J&J)

5.5.1 Velcade Sales 2010

5.5.2 Recent Developments

5.5.3 Velcade Sales Forecast, 2011-2015

5.5.4 Velcade Sales Forecast, 2016-2021

5.6 Arimidex (AstraZeneca)

5.6.1 Arimidex Sales 2010

5.6.2 Patent Expiry

5.6.3 Arimidex Sales Forecast, 2011-2015

5.6.4 Arimidex Sales Forecast, 2016-2021

5.7 Tarceva (Roche)

5.7.1 Tarceva Sales 2010

5.7.2 Patent Expiry

5.7.3 Tarceva Sales Forecast, 2011-2015

5.7.4 Tarceva Sales Forecast, 2016-2021

5.8 Sutent (Pfizer)

5.8.1 Sutent Sales 2010

5.8.2 Generic Launch Expected for Sutent 

5.8.3 Sutent Sales Forecast, 2011-2015

5.8.4 Sutent Sales Forecast, 2016-2021

5.8.5 Additional Indication Approval.

5.8.6 Late-Stage Clinical Trials for Additional Uses and Dosage Forms for Sutent

5.9 Nexavar (Bayer/Onyx)

5.9.1 Nexavar Sales 2010

5.9.2 Patent Expiry 

5.9.3 Nexavar Sales Forecast, 2011-2015

5.9.4 Nexavar Sales Forecast, 2016-2021

5.10 Sprycel (Bristol-Myers Squibb)

5.10.1 Sprycel Sales 2010

5.10.2 Patent Expiry 

5.10.3 Sprycel Sales Forecast, 2011-2015

5.10.4 Sprycel Sales Forecast, 2016-2021

6. R&D Pipeline for Small-Molecule Cancer Products6.1 An Overview6.2 Small-Molecule Lung Cancer Pipeline 20116.2.1 BIBW 2992 (Boehringer Ingelheim)6.2.2 Crizotinib (Pfizer)6.3 Small-Molecule Breast Cancer Pipeline 20116.3.1 Line Extensions6.3.2 Halaven (Eisai)6.4 Small-Molecule Colorectal Cancer Pipeline 20116.4.1 BAY 73-4506 (Bayer)6.4.2 KRX 0401 (Keryx/Aeterna Zentaris)6.5 Small-Molecule Stomach Cancer Pipeline 20116.5.1 Line Extensions6.5.2 Telatinib (ACT Biotech)6.6 Small-Molecule Prostate Cancer Pipeline 20116.6.1 MDV 3100 (Astellas/Medivation)6.6.2 CB7630 (Centocor Ortho Biotech)6.7. Small-Molecule Multiple Myeloma Pipeline, 20116.7.1 Proteasome Inhibitors: the Next Generation6.7.1.1 CEP 18770 (Cephalon)6.7.1.2 Marizomib (Nereus)6.7.1.3 MLN 9708 (Takeda)6.7.1.4 CEP 28331 (Cephalon)6.7.2 Immunomodulators: the Past or the Future for Myeloma Treatment?6.7.2.1 Afinitor (Novartis)6.7.2.2 E-Selectin Antagonists (GlycoMimetics)6.7.3 Histone Deacetylase Inhibitors: An Important New Sector6.7.3.1 Istodax (Celgene Corporation)6.7.3.2 Zolinza (Merck & Co.)6.7.3.3 AR 42 (Arno)6.7.3.4 Givinostat (Italfarmaco)6.7.3.5 HDAC6 Inhibitors (Acetylon)6.7.4 Kinase Inhibitors/Signal Transduction Blockers: The Largest Pipeline Sector6.7.4.1 Votrient (GlaxoSmithKline)6.7.4.2 Lenocta (VioQuest)6.7.4.3 Ruxolitnib (Novartis)6.7.4.4 Lestaurtnib (Cephalon)6.7.4.5 Masitnib (AB Science)6.7.4.6 AT 9283 (Astex Therapeutics)6.7.4.7 Dovitnib (Novartis)6.7.4.8 P276 (Piramal Life Sciences)6.7.4.9 PD332991 (Pfizer)6.7.4.10 ENMD 2076 (EntreMed)6.7.4.11 AT 7519 (Astex Therapeutics)6.7.4.12 MLN 8237 (Takeda)6.7.4.13 Estybon (Onconova)6.7.4.14 CX 4945 (Cylene)6.7.4.15 GDC 0941 (Roche)6.7.4.16 INK 128 (Intellikine)6.7.4.17 SF 1126 (Semafore)6.7.4.18 SNS 032 (Sunesis/Bristol-Myers Squibb)6.7.4.19 Sprycel (Otsuka/Bristol-Myers Squibb)6.7.4.20 TG 02 (Tragara/S*BIO)6.7.4.21 R763 (Rigel)6.7.5 Heat Shock Protein Modulators6.7.5.1 AUY 922 (Novartis)6.7.5.2 KW 2478 (Kyowa Hakko Kirin)6.7.5.3 NVP BEP800 (Novartis)6.7.6 Apoptosis Inducers: Four Products at Phase II6.7.6.1 GCS 100 (Prospect Therapeutics)6.7.6.2 Amplimexon (AmpliMed )6.7.6.3 Trisenox (Nippon Shinyaku)6.7.6.4 Noscapine (Cougar Biotechnology)6.7.6.5 BMS 833923 (Bristol-Myers Squibb)6.7.6.6 SNS 01-T (Senesco)6.7.7 Other Small-Molecule Myeloma Products6.7.7.1 Products in Phase II6.7.7.2 Amnolake (CytRx)6.7.7.3 Coprexa TM (Attenuon)6.7.7.4 Brostallacin (Cell Therapeutics)6.7.7.5 CYT 997 (YM BioSciences)6.7.7.6 ARRY 520 (Array BioPharma)6.7.7.7 Zinapar (Ziopharm)6.7.7.8 Products in Phase I6.7.7.9 Quadramet (EUSA Pharma)6.7.7.10 LC1 (Leuchemix)6.7.7.11 MLN 4924 (Takeda)6.7.7.12 OPB 31121 (Otsuka)6.7.7.13 Zalypsis (PharmaMar)6.7.7.14 Products in Preclinical Studies6.7.7.15 INNO 206 (CytRx)6.7.7.16 Ostabolin-C (Zelos)6.7.7.17 IRE1-alfa inhibitor (Mannkind)6.7.7.18 HIF Signalling Inhibitors (Elara)6.7.7.19 PS 031291 (Ligand) 6.7.7.20 SST 0001 (Sigma-Tau) 6.7.7.21 CGEN 928 (Compugen)6.7.7.22 USP7 Inhibitors (Progenra)6.8 Small-Molecule Epigenetic Therapy Pipeline, 20116.8.1 HDAC Inhibitors6.8.1.1 PXD-101 (Belinostat, TopoTarget/Spectrum Pharmaceuticals)6.8.1.2 LBH589 (Panobinostat, Novartis)6.8.1.3 Entinostat (Syndax Pharmaceuticals)6.8.1.4 4SC-201 (Resminostat, 4SC)6.8.1.5 MGCD-0103 (Mocetinostat, MethylGene)6.8.1.6 SB939 (S*BIO)6.8.1.7 ACY-1215 (Acetylon Pharmaceuticals)6.8.1.8 Valproic Acid6.8.2 DNMT Inhibitors6.8.2.1 SGI-110 (Astex Pharmaceuticals)6.8.2.2 CP-4200 (Clavis Pharma)

7. Qualitative Analysis of the Small-Molecule Cancer Therapies Market, 2011-2021

7.1 SWOT Chart for Small-Molecule Cancer Therapies Market 2011-2021

7.2 Strengths

7.2.1 Cancer Treatment has Proven Commercial Potential

7.2.2 High Profile Nature of Cancer

7.2.3 Off-Label Prescriptions are Common

7.2.4 Strong Drug Development Incentives

7.3 Weaknesses

7.3.1 Tumours and Multidrug Resistance (MDR) 

7.3.2 Pricing-Out the Developing World?

7.4 Opportunities

7.4.1 Cancer is a Key Business Area for the Pharmaceutical Industry

7.4.2 Rising Incidence of Cancer

7.4.1.1 Aging Populations

7.4.1.2 Smoking

7.4.1.3 Obesity

7.4.1.4 The Developing World

7.4.3 Greater Understanding of Cancer Biology Gives Opportunities in the Cancer Treatment Industry

7.4.4 Advanced Diagnostics with Pharmacogenomics: Impact on Cancer Therapies

7.4.5 Live Licensing and In-Life Testing

7.4.6 Convenience of Targeted Drugs versus Chemotherapy

7.5 Threats

7.5.1 Healthcare Spending Restraints Threaten Cancer Drug Revenues

7.5.2 The Cost-Effectiveness Debate

7.5.3 Governments are a Leading Payer for Drugs

7.5.4 Efficacy, Toxicity and Alternative Treatments

7.6 Biosimilars and Generics: Opportunity or Threat?

7.7 Personalised Medicine and Cancer

7.7.1 Biomarkers and Diagnostics

7.7.2 Small-Molecule (Metabolic) Biomarkers

7.7.3 Cancer Heterogeneity

7.7.4 Pharmacogenomics

7.7.5 Genome Screening

7.7.6 Theranostics

8. Research Interviews8.1 Dr Martin Bonde, CEO, EpiTherapeutics8.1.1 Potential for Histone Methyltransferase Inhibitors8.1.2 Future of Epigenetics Research8.1.3 Histone Methyltransferase Inhibitors on Market within Decade?8.1.4 Challenges in Developing Epigenetic Therapies8.1.5 Benefits of University Spin-Outs8.2 Dr Joanna Horobin, President and CEO, Syndax Pharmaceuticals8.2.1 On Challenges Facing Cancer Therapies8.2.2 On Selective Targeting of Therapies8.2.3 On Drug Resistance and Targeted Therapies8.2.4 On Drug Resistance and Market Opportunity8.2.5 On Entinostat, Lung and Breast Cancer Therapies

9. Conclusions

9.1 Small-Molecule Cancer Therapies Market Offers Promise

9.2 Leading Products in Small-Molecule Cancer Therapies Market, 2010

9.3 The US Will Remain the World's Largest Small-Molecule Cancer Therapies Market

9.4 India and China Will be the Fastest-Growing National Markets

9.5 R&D Pipelines for Many Cancer Types Are Strong

9.6 Concluding Remarks

List of Tables

Table 2.2 Most Common Cancers by Incidence, 2008

Table 2.3 Most Common Cancers by Mortality, 2008 & 2015

Table 2.4 Five-Year Survival Rates of Nine Cancers in the UK, 2009

Table 2.5 Categories of Anti-Cancer Drug, 2011

Table 2.6 Common Side Effects of Traditional Antineoplastic Chemotherapy

Table 2.7 Subcategories of TANs, 2011

Table 3.1 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2010-2015

Table 3.2 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2016-2021

Table 3.3 Small-Molecule Cancer Market: Top Ten Products - Sales and Market Shares, 2010, 2015 & 2021

Table 4.1 Leading Small-Molecule Cancer Therapies: National Market Forecasts, 2010-2021

Table 5.1 Glivec/Gleevec Sales for US and RoW, 2009 & 2010

Table 5.2 Glivec/Gleevec Sales Forecast, 2010-2015

Table 5.3 Glivec/Gleevec Sales Forecast, 2016-2021

Table 5.4 Glivec/Gleevec: Sales Drivers and Restraints, 2011-2021

Table 5.5 Revlimid Sales Forecast, 2010-2015

Table 5.6 Revlimid Sales Forecast, 2016-2021

Table 5.7 Revlimid: Sales Drivers and Restraints, 2011-2021

Table 5.8 Alimta Sales for US and RoW, 2009 & 2010

Table 5.9 Alimta Sales Forecast, 2010-2015

Table 5.10 Alimta Sales Forecast, 2016-2021

Table 5.11 Alimta: Sales Drivers and Restraints, 2011-2021

Table 5.12 Taxotere: Approved Indications, 2010

Table 5.13 Taxotere Sales by Region, 2009 & 2010 

Table 5.14 Taxotere Sales Forecast, 2010-2015

Table 5.15 Taxotere Sales Forecast, 2016-2021

Table 5.16 Taxotere: Sales Drivers and Restraints, 2011-2021

Table 5.17 Velcade Sales by Company, 2010

Table 5.18 Velcade Sales Forecast, 2010-2015

Table 5.19 Velcade Sales Forecast, 2016-2021

Table 5.20 Velcade: Sales Drivers and Restraints, 2011-2021

Table 5.21 Arimidex Sales for US and RoW, 2009 & 2010

Table 5.22 Arimidex Sales by Region, Q1-Q3 2010

Table 5.23 Arimidex Sales Forecast, 2010-2015

Table 5.24 Arimidex Sales Forecast, 2016-2021

Table 5.25 Arimidex: Sales Drivers and Restraints, 2011-2021

Table 5.26 Tarceva Sales Forecast, 2010-2015

Table 5.27 Tarceva Sales Forecast, 2016-2021

Table 5.28 Tarceva: Sales Drivers and Restraints, 2011-2021

Table 5.29 Sutent Sales Forecast, 2010-2015

Table 5.30 Sutent Sales Forecast, 2016-2021

Table 5.31 Sutent: Sales Drivers and Restraints, 2011-2021

Table 5.32 Nexavar Sales Forecast, 2010-2015

Table 5.33 Nexavar Sales Forecast, 2016-2021

Table 5.34 Nexavar Sales Drivers and Restraints, 2011-2021

Table 5.35 Sprycel Sales for US and RoW, 2009 & 2010

Table 5.36 Sprycel Sales Forecast, 2010-2015

Table 5.37 Sprycel Sales Forecast, 2016-2021

Table 5.38 Sprycel: Sales Drivers and Restraints, 2011-2021

Table 6.1 Number of Cancer Drug Pipeline Candidates by Indication, 2009 & 2011

Table 6.2 Abbreviations Used in Chapter 6

Table 6.3 Selected Small-Molecule Lung Cancer Pipeline Candidates in Phase III, 2010

Table 6.4 Selected Small-Molecule Lung Cancer Pipeline Candidates in Phase II, 2010

Table 6.5 Selected Small-Molecule Breast Cancer Pipeline in Phase II & III, 2010

Table 6.6 Selected Small-Molecule Colorectal Cancer Pipeline Candidates in Phase II & III, 2010

Table 6.7 Selected Small-Molecule Stomach Cancer Pipeline Candidates in Phase II & III, 2010

Table 6.8 Selected Small-Molecule Prostate Cancer Pipeline Candidates in Phase II & III, 2010

Table 6.9 Small-Molecule Pipeline Products for Multiple Myeloma, 2011

Table 6.10 Small-Molecule Multiple Myeloma Pipeline: Proteasome Inhibitors, 2011

Table 6.11 Small-Molecule Multiple Myeloma Pipeline: Immunomodulators, 2011

Table 6.12 Small-Molecule Multiple Myeloma Pipeline: Histone Deacetylase Inhibitors, 2011

Table 6.13 Small-Molecule Multiple Myeloma Pipeline: Kinase Inhibitor/Signal Transduction Blockers, 2011

Table 6.14 Small-Molecule Multiple Myeloma Pipeline: Heat Shock Protein Modulators, 2011

Table 6.15 Small-Molecule Multiple Myeloma Pipeline: Apoptosis Inducers, 2011

Table 6.16 Other Small-Molecule Myeloma Products: Phase II Pipeline, 2011

Table 6.17 Other Small-Molecule Myeloma Products: Phase I Pipeline, 2011

Table 6.18 Other Small-Molecule Myeloma Products: Preclinical Pipeline, 2011

Table 6.19 Selected Small-Molecule HDAC Inhibitor Pipeline Candidates, 2011

Table 6.20 Ongoing Clinical Trials for PXD-101 (Belinostat), 2011

Table 7.1 SWOT Analysis of World Small-Molecule Cancer Drugs Market: Strengths and Weaknesses, 2011-2021

Table 7.2 SWOT Analysis of World Small-Molecule Cancer Drugs Market: Opportunities and Threats, 2011-2021

Table 9.1 Small-Molecule Cancer Drug Market: Top Ten Products - Sales and Market Shares, 2010

Table 9.2 Small-Molecule Cancer Drugs Market by Country, 2010, 2015, 2018 & 2021

List of Figures

Figure 2.2 Most Common Cancers by Incidence, 2008

Figure 2.3 Most Common Cancers by Mortality, 2008

Figure 2.4 Most Common Cancers by Mortality, 2015

Figure 2.5 Five-Year Survival Rates of Nine Cancers in the UK, 2009

Figure 3.1 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2010-2015

Figure 3.2 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2016-2021

Figure 3.3 Small-Molecule Cancer Therapies: Sales for Leading Products, 2010

Figure 3.4 Small-Molecule Cancer Therapies: Sales for Leading Products, 2015

Figure 3.5 Small-Molecule Cancer Therapies: Sales for Leading Products, 2018

Figure 3.6 Small-Molecule Cancer Therapies: Sales for Leading Products, 2021

Figure 4.1 Leading National Small-Molecule Cancer Therapies: Market Forecasts, 2010-2021

Figure 4.2 National Small-Molecule Cancer Therapies: Market Forecasts, Lower Range, 2010-2021

Figure 4.3 Small-Molecule Cancer Therapies: Sales in Leading National Markets, 2010

Figure 4.4 Small-Molecule Cancer Therapies: Sales in Leading National Markets, 2015

Figure 4.5 Small-Molecule Cancer Therapies: Sales in Leading National Markets, 2018

Figure 4.6 Small-Molecule Cancer Therapies: Sales in Leading National Markets, 2021

Figure 5.1 Glivec/Gleevec Sales for US and RoW, 2010

Figure 5.2 Glivec/Gleevec Sales Forecast, 2010-2021

Figure 5.3 Revlimid Sales Forecast, 2010-2021

Figure 5.4 Alimta Sales for US and RoW, 2010

Figure 5.5 Alimta Sales Forecast, 2010-2021

Figure 5.6 Taxotere Sales by Region, 2010

Figure 5.7 Taxotere Sales Forecast, 2010-2021

Figure 5.8 Velcade Sales by Company, 2010

Figure 5.9 Velcade Sales Forecast, 2010-2021

Figure 5.10 Arimidex Sales by Region, Q1-Q3 2010

Figure 5.11 Arimidex Sales by Region, 2010

Figure 5.12 Arimidex Sales Forecast, 2010-2021

Figure 5.13 Tarceva Sales Forecast, 2010-2021

Figure 5.14 Sutent Sales Forecast, 2010-2021

Figure 5.15 Nexavar Sales Forecast, 2010-2021

Figure 5.16 Sprycel Sales for US and RoW, 2010

Figure 5.17 Sprycel Sales Forecast, 2010-2021

Figure 6.1 Number of Cancer Drug Pipeline Candidates by Indication, 2009 & 2011

Figure 9.1 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2010, 2012, 2015, 2018 & 2021 

Companies Listed

AB Science 

Abbott Laboratories 

Abgenix

Abraxis BioScience

Acceleron

Ascenta Therapeutics

Acetylon

Actavis

ACT Biotech

Active Biotech

Adeona

AERES Biomedical

Aeterna Zentaris

Agennix

Alexion

Alza

Allos Therapeutics

American Society of Clinical Oncology (ASCO)

American Society of Hematology (ASH)

Amgen

AmpliMed

Anthrogenesis

Apexigen

Apotex

APP Pharmaceuticals (part of the Fresenius Kabi Group)

ARIAD Pharmaceuticals

Arizona University

Arno 

Array BioPharma

Ascenta Therapeutics

Astellas Pharma

Astex Therapeutics

AstraZeneca

Attenuon

AVEO Pharmaceuticals

Barr Laboratories

Bayer

Biogen Idec

BioInvent

Bionovo

Biotech Research and Innovation Centre (BRIC), University of Copenhagen

Biotest

BioWa

BiPar Sciences (subsidiary of Sanofi)

Boehringer Ingelheim

Bristol-Myers Squibb

British Biotech

BTG

Canadian National Research Council

Cancer Research Technology 

Cancer Research UK

Cancer Science Institute of Singapore (CSI Singapore)

Celanese

Celgene

Cell Therapeutics

Centocor Ortho Biotech

Cephalon

Cetus Corporation

Chiron

Choongwae

Cipla

Clavis Pharma

Cleveland Clinic

Columbia University

Compugen

Concordia Pharmaceuticals

Constellation Pharmaceuticals

Cougar Biotechnology

Crinos

CTI Technologies

CuraGen

CureVac

Cyclacel Pharmaceuticals

CyDex

Cylene

Cytogen

Cytokinetics

CytRx

Daiichi Sankyo

Dako 

Dana Farber Cancer Institute

Endocyte

Elan

EntreMed

Dendreon

Dr. Reddy's Laboratories

Eisai

Elara Pharmaceuticals 

Eleison Pharmaceuticals

Eli Lilly

European Medicines Agency (EMEA/EMA)

European Molecular Biology Laboratory

Endocyte

EntreMed

EpiTherapeutics

Epizyme

EUSA Pharma

Exelixis

Facet Biotech

Food and Drug Administration (US FDA)

Fresenius Kabi

Genentech (now part of Roche)

Generex Biotechnology

Genmab

Genta

Genzyme 

Geron

GlaxoSmithKline (GSK)

Gloucester Pharmaceuticals

GlycoGenesys

GlycoMimetics

GPC Biotech

Greenwich Therapeutics

GTC Biotherapeutics

Handok

Harvard University

Hospira

Human Genome Sciences

IkerChem

ILEX Oncology

ImClone Systems (a subsidiary of Eli Lilly)

Immune System Therapeutics

ImmunoGen

Incyte

Infinity Pharmaceuticals

Innate Pharma

Intas Biopharmaceuticals

Intellikine

International Cancer Genome Consortium

International Myeloma Working Group

Introgen Therapeutics

Isis Pharmaceuticals

Italfarmaco

Janssen-Cilag

Johnson & Johnson (J&J)

Kaken

Karyopharm Therapeutics

Keryx Biopharmaceuticals

Keyaku Zentaris

Kosan Biosciences

Kyowa Hakko Kirin

Leuchemix

Les Laboratoires Servier

Ligand

Lipomed

Lonza

Mannkind

Marlborough Research and Development

Marshall Edwards

MD Anderson Cancer Center

MedImmune

Medivation

Merck & Co.

Merck KGaA 

Merck Serono (part of Merck KGaA)

MethylGene

Micromet

Millennium Pharmaceuticals

MorphoSys

Mount Sinai Medical Center [US]

Multiple Myeloma Research Consortium

Multiple Myeloma Research Foundation

Mylan

Natco Pharma

National Cancer Institute (NCI) [US]

National Cancer Institute (US)

National Health Service (NHS) [UK]

National Institute for Clinical Excellence (NICE) [UK]

National University Cancer Institute Singapore (NCIS)

NCIC Clinical Trials Group

Nektar Therapeutics

Nereus

Nerviano Medical Sciences

Nippon Shinyaku

Novartis

Novo Nordisk

Novogen

Ohio State University

OncoGenex Pharmaceuticals

Oncova

Ono Pharmaceuticals

Onyx Pharmaceuticals

Ortho Biotech

Otsuka

Oxford University

Par Pharmaceutical

PDL BioPharma

Pfizer

Pharmaceutical Research and Manufacturers of America (PhRMA) [US]

Pharmacia 

Pharmacopeia

Pharmacyclics

PharmaMar

Pharmion

Pierre Fabre

Pipex

Piramal Life Sciences

PIramed

PolaRx Biopharmaceuticals

Poniard Pharmaceuticals

Proacta 

Progenra

Prospect Therapeutics

Protein Design

Proteolix

R&R

Radient Pharmaceuticals

Regeneron 

Rigel

Roche

Rockefeller University

Roxane Laboratories

Salk Institute for Biological Studies

S*BIO

Sandoz (part of Novartis)

Sanofi (sanofi-aventis)

Scancell

Schering-Plough

Scripps Institution of Oceanography

Seattle Genetics

Semafore

Senesco

Shire

Sigma-Tau 

Signal Pharmaceuticals

Sirton

Sloan-Kettering Institute 

Spectrum Pharmaceuticals

Stada Arzneimittel

Sun Pharmaceuticals

Sunesis

Syndax Pharmaceuticals

Taiho Pharma

Takeda

Tapestry Pharmaceuticals

TargeGen

Teva Pharmaceutical Industries

Texas A&M University

Threshold Pharmaceuticals

TMRC

Toko

TopoTarget 

Tragara

Tufts University

University of Basel PharmaCenter (PharmaCenter Basel)

University of Cambridge

University of Kentucky College of Pharmacy

University of Michigan

University of San Diego

US National Comprehensive Cancer Network

Vernalis

VioQuest

Wayne State University

WILEX

World Health Organization (WHO)

Xencor

XOMA

XTL Biopharmaceuticals

Yakult Honsha

Yeda Research and Development Company

YM Biosciences

Zelos

Zeltia

Zenyaku Kogyo

Zeria

Ziopharm 

To order this report:Biological Therapy Industry: Small-Molecule Targeted Cancer Therapies: World Market 2011-2021

More  

Market Research Report

Check our  

Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker